Project publications


  1. Appelman MD, Chakraborty A, Protzer U, McKeating JA and van de Graaf, SFJ. (2017).
    N-Glycosylation of the Na+-Taurocholate Cotransporting Polypeptide (NTCP) Determines Its Trafficking and Stability and Is Required for Hepatitis B Virus Infection.
    Plos ONE. 12(1):e0170419.
  1. Bandiera S, Pernot S, El Saghire H, Durand SC, Thumann C, Crouchet E, Ye T, Fofana I, Oudot MA, Barths J, Schuster C, Pessaux P, Heim MH, Baumert TF, Zeisel MB. (2016).
    Hepatitis C Virus-Induced Upregulation of MicroRNA miR-146a-5p in Hepatocytes Promotes Viral Infection and Deregulates Metabolic Pathways Associated with Liver Disease Pathogenesis.
    J Virol. 90, 6387-400.
  1. Baumert TF, Jühling F, Ono A, Hoshida Y. (2017).
    Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals.
    BMC Med. 5(1):52.
  1. Baumert TF, Berg T, Lim JK, Nelson DR. (2018).
    Status of Direct-acting Antiviral Therapy for HCV Infection and Remaining Challenges.
    Gastroenterology. pii: S0016-5085(18)35155-2. doi: 10.1053/j.gastro.2018.10.024. [Epub ahead of print]. Review.
  1. Bollard J, Miguela V, Ruiz de Galarreta M, Venkatesh A, Bian CB, Roberto MP, Tovar V, Sia D, Molina-Sánchez P, Nguyen CB, Nakagawa S, Llovet JM, Hoshida Y, Lujambio A.(2016).
    Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma.
    Gut. 66/7, 1286-1296.
  1. Cardo L, Nawroth I, Cail PJ, McKeating JA and Hannon MJ. (2018).
    Metallo supramolecular cylinders HIV-1 TAR-TAT complex formation and viral infection in cellulo.
    Science Reports. 8:13342.
  1. Colpitts CC, Tawar RG, Mailly L, Thumann C, Heydmann L, Durand SC, Xiao F, Robinet E, Pessaux P, Zeisel MB, Baumert TF. (2017).
    Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape.
    Gut. pii: gutjnl-2016-312577. [Epub ahead of print]
  1. Colpitts CC, Lupberger J, Baumert TF. (2016).
    Multifaceted role of E-cadherin in hepatitis C virus infection and pathogenesis.
    Proc Natl Acad Sci U S A. 13(27), 7298-300.
  1. Colpitts CC, Baumert TF. (2017).
    SMAD about hepatitis C virus cell entry and liver disease.
    Gastroenterology. 152(1), 21-23.
  1. Colpitts CC, Baumert TF. (2017).
    SCARB1 variants and HCV infection: Host susceptibility is lost in translation.
    J Hepatol. 67(2):211-213.
  1. Colpitts CC, Baumert TF. (2017).
    Claudins in viral infection: from entry to spread.
    Pflugers Arch. 469(1):27-34. doi: 10.1007/s00424-016-1908-4. Review.
  1. Colpitts CC, Chung RT, Baumert TF. (2017).
    Entry Inhibitors: A Perspective for Prevention of Hepatitis C Virus Infection in Organ Transplantation.
    ACS Infect Dis. 3(9):620-623. doi:10.1021/acsinfecdis.7b00091. Epub 2017 Aug 16. 2869. Review.
  1. Crouchet E, Lefèvre M, Verrier ER, Oudot MA, Baumert TF, Schuster C. (2017).
    Extracellular lipid-free apolipoprotein E inhibits HCV replication and induces ABCG1-dependent cholesterol efflux.
    Gut. 66(5), 896-907.
  1. Crouchet E, Wrensch F, Zeisel M, Schuster C, Baumert TF. (2018).
    Host-targeting therapies for hepatitis C virus infection: current developments and future applications.
    Therapeutic Advances in Gastroenterology. 66(5), 896-907.
  1. Desombere I, Mesalam AA, Urbanowicz RA, Van Houtte F, Verhoye L, Keck ZY, Farhoudi A, Vercauteren K, Weening KE, Baumert TF, Patel AH, Foung SKH, Ball J, Leroux-Roels G, Meuleman P. (2017).
    A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo.
    Antiviral Res. Oct 23. pii: S0166-3542(17)30430-8.
  1. Eller C, Heydmann L, Colpitts CC, Verrier ER, Schuster C, Baumert TF. (2018).
    The functional role of sodium taurocholate cotransporting polypeptide NTCP in the life cycle of hepatitis B, C and D viruses.
    Cell Mol Life Sci. 75(21), 3895-3905. Review.
  1. Elßner C, Goeppert B, Longerich T, Scherr AL, Stindt J, Nanduri LK, Rupp C, Kather JN, Schmitt N, Kautz N, Breuhahn K, Ismail L, Heide D, Hetzer J, García-Beccaria M, Hövelmeyer N, Waisman A, Urbanik T, Mueller S0, Gdynia G, Banales JM, Roessler S, Schirmacher P, Jäger D, Schölch S, Keitel V, Heikenwalder M, Schulze-Bergkamen H, Köhler BC. (2018).
    Nuclear Translocation of RELB is Increased in Diseased Human Liver and Promotes Ductular Reaction and Biliary Fibrosis in Mice.
    Gastroenterology. pii: S0016-5085(18)35260-0. [Epub ahead of print]
  1. Farquhar MJ, Humphreys IS, Rudge SA, Wilson GK, Bhattacharya B, Ciaccia M, Hu K, Zhang Q, Mailly L, Reynolds GM, Ashcroft M, Balfe P, Baumert TF, Roessler S, Wakelam MJO, McKeating JA. (2017).
    Autotaxin-lysophosphatidic acid receptor signalling regulates hepatitis C virus replication.
    J Hepatol. 66, 919-929.
  1. Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul J-L, Schirmacher P, Vilgrain V. (2018).
    EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma, European Association for the Study of the Liver.
    J Hepatol. 69:182-236.
  1. Georgilis A, Klotz S, Hanley CJ, Herranz N, Weirich B, Morancho B, Leote AC, D'Artista L, Gallage S, Seehawer M, Carroll T, Dharmalingam G, Wee KB, Mellone M, Pombo J, Heide D, Guccione E, Arribas J, Barbosa-Morais NL, Heikenwalder M, Thomas GJ, Zender L, Gil J. (2018).
    PTBP1-Mediated Alternative Splicing Regulates the Inflammatory Secretome and the Pro-tumorigenic Effects of Senescent Cells.
    Cancer Cell. 34(1):85-102.e9.
  1. Goeppert B, Toth R, Singer S, Albrecht T, Lipka DB, Lutsik P, Brocks D, Baehr M, Muecke O, Assenov Y, Gu L, Endris V, Stenzinger A, Mehrabi A, Schirmacher P, Plass C, Weichenhan D, Roessler S. (2019).
    Integrative analysis defines distinct prognostic subgroups of intrahepatic cholangiocarcinoma.
    Hepatology. [Epub ahead of print]
  1. Gonçalves-Carneiro D, McKeating JA and Bailey D. (2017).
    The Measles Virus Receptor SLAMF1 Can Mediate Particle Endocytosis.
    J Virology. 91/7, e02255-16.
  1. Grove J, Hu K, Farquhar MJ, Goodall M, Walker L, Jamshad M, Drummer HE, Bill RM, Balfe P and McKeating JA. (2017).
    A new panel of epitope mapped monoclonal antibodies recognizing the prototypical tetraspanin CD81.
    Wellcome Open Research. 2:82.
  1. Haqshenas G, Wu J, Simpson KJ, Daly RJ, Netter HJ, Baumert TF, Doerig C. (2017).
    Signalome-wide assessment of host cell response to hepatitis C virus.
    Nat Commun. 8:15158.
  1. Hösel M, Quasdorff M, Ringelhan M, Kashkar H, Debey-Pascher S, Sprinzl MF, BockmannJH, ArzbergerA, Webb D, von Olshausen G, Weber A, Schultze JL, Büning H, Heikenwalder M, Protzer, U. (2017).
    Signalome-wide assessment of host cell response to hepatitis C virus.
    Cellular and Molecular Gastroenterology and Hepatology. 4: 339-363.
  1. Keck ML, Wrensch F, Pierce BG, Baumert TF, Foung S. (2018).
    Mapping determinants of virus neutralization and viral escape for rational design of a hepatitis C virus vaccine.
    Frontiers in Immunology. 9:1194. Review.
  1. Khera T, Todt D, Vercauteren K, McClure CP, Verhoye L, Farhoudi A, Bhuju S, Geffers R, Baumert TF, Steinmann E, Meuleman P,
    Pietschmann T, Brown RJ. (2017).
    Tracking HCV protease population diversity during transmission and susceptibility of founder populations to antiviral therapy.
    Antiviral Research. 139, 129-137.
  1. Ko C, Chakraborty A, Chou WM, Hasreiter J, Wettengel JM, Stadler D, Bester R, Asen T, Zhang K, Wisskirchen K, McKeating JA, Ryu WS, Protzer U. (2018).
    Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels.
    Journal of Hepatology. [Epub ahead of print]
  1. Labgaa I, Villacorta-Martin C, D'Avola D, Craig AJ, von Felden J, Martins-Filho SN, Sia D, Stueck A, Ward SC, Fiel MI, Mahajan M, Tabrizian P, Thung SN, Ang C, Friedman SL, Llovet JM, Schwartz M, Villanueva A. (2018).
    A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma.
    Oncogene. 37:3740-3752.
  1. Lai AG, Forde D, Chang WH, Zhuang X Rubio CO, Balfe P and McKeating JA. (2018).
    Glucose and glutamine availability regulate HepG2 hepatoma transcriptional responses.
    Wellcome Open Research. 3:126.
  1. Lencioni R, Montal R, Torres F, Park JW, Decaens T, Raoul JL, Kudo M, Chang C, Ríos J, Boige V, Assenat E, Kang YK, Lim HY, Walters I,
    Llovet JM. (2017).
    Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC.
    J Hepatol. 66/6, 1166-1172.
  1. Li Y, Xia Y, Han M, Chen G, Zhang D, Thasler W, Protzer U, Ning Q. (2017).
    IFN-α-mediated Base Excision Repair Pathway Correlates with Antiviral Response Against Hepatitis B Virus Infection.
    Scientific Reports. Oct 5;7(1):12715.
  1. Ligat G., Schuster C., Baumert T.F. (2019).
    HBV core variants, liver fibrosis and hepatocellular carcinoma.
    Hepatology. 65, 5-8. Review.
  1. Lim TR, Hazelhurst J, Oprescu AI, Armstrong MJ, Abdullah SF, Davies NP, Flintham R, Balfe P, Mutimer DJ, McKeating JA and Tomlinson, JW. (2018).
    Hepatitis C virus infection is associated with hepatic and adipose tissue insulin resistance that improves post viral cure.
    Clin Endocrinolgy. in press
  1. Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G. (2016).
    Hepatocellular carcinoma.
    Nat Rev Dis Primers. 2:16018.
  1. Llovet JM, Montal R, Sia D, Finn S. (2018).
    Molecular therapies and precision medicine for hepatocellular carcinoma.
    Nat Rev Clin Oncol. 15:599-616.
  1. Llovet JM, Pavel M, Rimola J, Diaz MA, Colmenero J, Saavedra-Perez D, Fondevila C, Ayuso C, Fuster J, Ginès P, Bruix J, Garcia-Valdecasas JC. (2018).
    Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria).
    Liver Transpl. 24:369-379.
  1. Lorentzen A, Becker PF, Kosla J, Saini M, Weidele K, Ronchi P, Klein C, Wolf MJ, Geist F, Seubert B, Ringelhan M, Mihic-Probst D, Esser K, Roblek M, Kuehne F, Bianco G, O'Connor T, Müller Q, Schuck K, Lange S, Hartmann D, Spaich S, Groß O, Utikal J, Haferkamp S, Sprick MR, Damle-Vartak A, Hapfelmeier A, Hüser N, Protzer U, Trumpp A, Saur D, Vartak N, Klein CA, Polzer B, Borsig L, Heikenwalder M. (2018).
    Single cell polarity in liquid phase facilitates tumour metastasis.
    Nature Communications. 9(1):887.
  1. Manzoni G, Marinach C, Topçu S, Briquet S, Grand M, Tolle M, Gransagne M, Lescar J, Andolina C, Franetich JF, Zeisel MB, Huby T, Rubinstein E, Snounou G, Mazier D, Nosten F, Baumert TF, Silvie O. (2017).
    Plasmodium P36 determines host cell receptor usage during sporozoite invasion.
    eLife. 6. pii: e25903.
  1. Martinez-Quetglas I, Pinyol R, Dauch D, Torrecilla S, Tovar V, Moeini A, Alsinet C, Portela A, Rodriguez-Carunchio L, Solé M, Lujambio A, Villanueva A, Thung S, Esteller M, Zender L, Llovet JM. (2016).
    IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Gastroenterology 151(6):1192-1205.
  1. McNaughton AL, D’Arienzo V, Ansari A, Lumley S, Littlejohn M, Revill P, McKeating JA and Matthews, PC. (2018).
    Insights From Deep Sequencing of the HBV Genome-Unique, Tiny, and Misunderstood.
    Gastroenterology 156; 384-399.
  1. Moeini A, Sia D, Zhang Z, Camprecios G, Stueck A, Dong H, Montal R, Torrens L, Martinez-Quetglas I, Fiel MI, Hao K, Villanueva A, Thung SN, Schwartz ME, Llovet JM. (2017).
    Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
    J Hepatol. 66(5):952-961.
  1. Moeini A, Sia D, Bardeesy N, Mazzaferro V, Llovet JM. (2016).
    Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma.
    Clin Cancer Res. 22(2):291-300.
  1. Mohsen Malehmir, Dominik Pfister, Suchira Gallage, Marta Szydlowska, Donato Inverso, Elena Kotsiliti, Valentina Leone, Moritz Peiseler, Bas G.J. Surewaard, Dominik Rath, Sheikh Adnan Ali, Monika Julia Wolf, Hannah Drescher, Marc E. Healy, Daniel Dauch, Daniela Kroy, Oliver Krenkel, Marlene Kohlhepp, Thomas Engleitner, Alexander Olkus, Tjeerd Sijmonsma, Julia Volz, Carsten Deppermann, David Stegner, Patrick Helbling, César Nombela-Arrieta, Anahita Rafiei, Martina Steurer, Marcel Rall, Florian Baku, Caroline L. Wilson, Jack Leslie, Tracy O`Connor, Christopher C. Weston, David H. Adams, Lozan Sheriff, Ana Teijeiro, Marco Prinz, Ruzhica Bogeska, Natasha Anstee, Malte Bongers, Mike Notohamiprodjo, Tobias Geisler, Dominic J. Withers, Jerry Ware, Derek A. Mann, Hellmut Augustin, Alexandros Vegiopoulos, Michael Milsom, Adam J. Rose, Patricia F. Lalor, Josep M. Llovet, Roser Pinyol, Frank Tacke, Roland Rad, Nabil Djouder, Paul Kubes, Percy A. Knolle, Kristian Unger, Lars Zender, Bernhard Nieswandt, Meinrad Gawaz, Achim Weber and Mathias Heikenwalder.
    Platelet GPIba is a mediator and potential interventional target for NASH and subsequent liver cancer.
    Nature Medicine. in press 02 2018.
  1. Pinyol R, Montal R, Bassaganyas L, Sia D, Takayama T, Chau GY, Mazzaferro V, Roayaie S, Lee HC, Kokudo N, Zhang Z, Torrecilla S, Moeini A, Rodriguez-Carunchio L, Gane E, Verslype C, Croitoru AE, Cillo U, de la Mata M, Lupo L, Strasser S, Park JW, Camps J, Solé M, Thung SN, Villanueva A, Pena C, Meinhardt G, Bruix J, Llovet JM (2018).
    Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma.
    Gut. pii: gutjnl-2018-316408.
  1. Protzer U. (2017).
    Viral hepatitis: The bumpy road to animal models for HBV infection.
    Nature Reviews in Gastroenterology and Hepatology. 14(6):327-328.
  1. Ringelhan, M, McKeating JA and Protzer U. (2017).
    Viral hepatitis and liver cancer.
    Phil Trans Royal Society. 372(1732).
  1. Ringelhan M, Pfister D, O'Connor T, Pikarsky E, Heikenwalder M. (2018).
    The immunology of hepatocellular carcinoma.
    Nature Immunology. 19(3):222-232. Epub 2018 Jan 29. Review.
  1. Roca Suarez AA, Van Renne N, Baumert TF, Lupberger J. (2018).
    Viral manipulation of STAT3: evade, exploit and injure.
    Plos Pathogens. 14(3):e1006839. eCollection 2018 Mar. Review.
  1. Roca Suarez AA, Baumert TF, Lupberger J. (2018).
    Beyond viral dependence: the pathological consequences of HCV-induced EGF signaling.
    J. Hepatol. 69(3):564-566. Review.
  1. Sia D, Jiao Y, Martinez-Quetglas I, Kuchuk O, Villacorta-Martin O, Castro de Moura M, Putra J, Camprecios G, Bassaganyas L, Akers N, Losic B, Waxman S, Thung SN, Mazzaferro V, Esteller M, Friedman SL, Schwartz M, Villanueva A, Llovet, J.M. (2017).
    Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features.
    Gastroenterology. 153(3):812-826.
  1. Sia D, Villanueva A, Friedman SL, Llovet JM. (2017).
    Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis.
    Gastroenterology. 152:745-761.
  1. Sia D, Llovet JM. (2017).
    Liver cancer: Translating '-omics' results into precision medicine for hepatocellular carcinoma.
    Nat Rev Gastroenterol Hepatol. 14:571-572.
  1. Taouli B, Hoshida Y, Kakite S, Chen X, Tan PS, Sun X, Kihira S, Kojima K, Toffanin S, Fiel MI, Hirschfield H, Wagner M, Llovet JM. (2017).
    Imaging-based surrogate markers of transcriptome subclasses and signatures in hepatocellular carcinoma: preliminary results.
    Eur Radiol. 27(11):4472-4481.
  1. Torrecilla S, Sia D, Harrington AN, Zhang Z, Cabellos L, Cornella H, Moeini A, Camprecios G, Leow WQ, Fiel MI, Hao K, Bassaganyas L, Mahajan M, Thung SN, Villanueva A, Florman S, Schwartz ME, Llovet JM. (2017).
    Trunk events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma.
    Journal of Hepatology. 67:1222-1231.
  1. Tovar V, Cornella H, Moeini A, Vidal S, Hoshida Y, Sia D, Peix J, Cabellos L,  Alsinet C, Torrecilla S, Martinez-Quetglas I, Lozano JJ, Desbois-Mouthon C, Solé  M, Domingo-Domenech J, Villanueva A, Llovet JM. (2017).
    Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma.
    Gut. Mar;66(3):530-540.
  1. Van Renne N, Roca Suarez AA, Duong FHT, Gondeau C, Calabrese D, Fontaine N, Ababsa A, Bandiera S, Croonenborghs T, Pochet N, De Blasi V, Pessaux P, Piardi T, Sommacale D, Ono A, Chayama K, Fujita M, Nakagawa H, Hoshida Y, Zeisel MB, Heim MH, Baumert TF,
    Lupberger J. (2017).
    miR-135a-5p-mediated downregulation of protein-tyrosine phosphatase delta is a candidate driver of HCV-associated hepatocarcinogenesis.
    Gut. 67(5):953-962 .
  1. Verrier ER, Colpitts CC, Zona L, Bach C, Heydmann L, Xiao F, Thumann C, Schuster C, Sureau C, McKeating JA, Hoshida Y, Zeisel MB and Baumert TF. (2017).
    Solute carrier NTCP regulates expression of innate antiviral immune responses targeting viral cell entry into hepatocytes.
    Cell Reports. 17:1357- 1368.
  1. Verrier ER, Schuster C, Baumert TF. (2017).
    Advancing hepatitis B virus entry inhibitors.
    J. Hepatol. 66(4), 677-679. doi: 10.1016/j.jhep.2016.11.028.
  1. Verrier ER, Yim SA, Heydmann L, El Saghire H, Bach C, Turon-Lagot V, Mailly L, Durand SC, Lucifora J, Durantel D, Pessaux P, Manel N, Hirsch I, Zeisel MB, Pochet N, Schuster C, Baumert TF. (2018).
    Hepatitis B virus evasion from cGAS sensing in human hepatocytes.
    Hepatology. 68(5):1695-1709.
  1. Vogel A, Cervantes A, Chau I, Daniele B, Llovet J, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech CJ, Arnold D, Martinelli E. (2018).
    ESMO Guidelines Committee. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2018;29:iv238-iv255.
  1. Von Olshausen G, Quasdorff M, Bester R, Arzberger S, Ko C, van de Klundert M, Zhang K, Odenthal M, Ringelhan M, Niessen CM, Protzer U. (2018).
    Hepatitis B virus promotes β-catenin-signalling and disassembly of adherens junctions in a Src kinase dependent fashion.
    Oncotarget. Sep 21;9(74): 339547-60.
  1. Wan S, Meyer AS, Weiler SME, Rupp C, Tóth M, Sticht C, Singer S, Thomann S, Roessler S, Schorpp-Kistner M, Schmitt J, Gretz N, Angel P, Tschaharganeh DF, Marquardt J, Schirmacher P, Pinna F, Breuhahn K. (2018).
    Cytoplasmic localization of the cell polarity factor scribble supports liver tumor formation and tumor cell invasiveness.
    Hepatology. 67(5):1842-1856.
  1. Wolski D, Foote PK, Chen DY, Lewis-Ximenez LL, Fauvelle C, Aneja J, Walker A, Tonnerre P, Torres-Cornejo A, Kvistad D, Imam S, Waring MT, Tully DC, Allen TM, Chung RT, Timm J, Haining WN, Kim AY, Baumert TF, Lauer GM. (2017).
    Early Transcriptional Divergence Marks Virus-Specific Primary Human CD8(+) T Cells in Chronic versus Acute Infection.
    Immunity. 47(4):648-663.e8.
  1. Wrensch F, Crouchet E, Ligat G, Zeisel MB, Keck ZY, Foung SKH, Schuster C, Baumert TF.(2018).
    Hepatitis C Virus-Apolipoprotein Interactions and Immune Evasion and their impact on HCV vaccine design.
    Frontiers in Immunology. 9:1436. Review.
  1. Wu T, Heuillard E, Lindner V, Bou About G, Ignat M, Dillenseger JP, Anton N, Dalimier E, Gossé F, Fouré G, Blindauer F, Giraudeau C, El-Saghire H, Bouhadjar M, Calligaro C, Sorg T, Choquet P, Vandamme T, Ferrand C, Marescaux J, Baumert TF, Diana M, Pessaux P, Robinet E. (2016).
    Multimodal imaging of a humanized orthotopic model of hepatocellular carcinoma in immunodeficient mice.
    Sci Rep. 6, 35230.
  1. Xia Y, Cheng X, Blossey CK, Wisskirchen K, Esser K, Protzer U. (2017).
    Secreted Interferon-Inducible Factors Restrict Hepatitis B and C Virus Entry In Vitro.
    J Immunol Res. 4828936.
  1. Xia Y, Protzer U. (2017).
    Control of HBV virus by Cytokines.
    Viruses. 20:9(1), pii: E18.
  1. Virzì A, Roca Suarez AA, Baumert TF, Lupberger J. (2018).
    Oncogenic Signaling Induced by HCV Infection.
    Viruses. 10(10). pii: E538. Review.
  1. Zeisel MB, Dhawan P, Baumert TF. (2018).
    Tight junction proteins in gastrointestinal and liver disease.
    Gut. 2018 Oct 8. pii: gutjnl-2018-316906. [Epub ahead of print]. Review.
  1. Zhang Z, Meszaros G, He WT, Xu Y, de Fatima Magliarelli H, Mailly L, Mihlan M, Liu Y, Puig Gámez M, Goginashvili A, Pasquier A, Bielska O, Neven B, Quartier P, Aebersold R, Baumert TF, Georgel P, Han J, Ricci R. (2017).
    Protein kinase D at the Golgi controls NLRP3 inflammasome activation.
    J Exp Med. 214(9):2671-2693.
  1. Zhuang X, Magri A, Lai AG, Hill M, Chang WH, Donald C, Wing P, Brown R, Qin X, Parsons AL, Simmonds P, Roessler S, Baumert TF, Ray D, Loudon A, Balfe P, Butterworth S, Kohl A, Jopling CL, Zitzmann N and McKeating JA. (2019).
    The circadian clock BMAL1 and Rev-Erbα regulate flavivirus replication.
    Nature Comms. 10(1):377.
  1. Zhuang X, Lai AG, McKeating JA, Rowe A and Balfe P. (2018).
    Daytime variation in hepatitis C virus replication kinetics post liver transplant.
    Wellcome Open Research. 3:96.
  1. Zhuang X, Rambhatla SB, Lai A and McKeating JA. (2017).
    Interplay between circadian clock and viral infection.
    J Molecular Medicine. 95; 1283-1289.